Matt Pillar

Featured in: Favicon

bioprocessonline.com Favicon

supplychainmarket.com

Articles

11.15.24 -- Inside J&J's Many-Indication mAb

Nov 15, 2024 | bioprocessonline.com | Tyler Menichiello |Matt Pillar |Ger Brophy

No matter how robust and consistent your assays are today, the time will come when a tech transfer, a scale-up, a supplier change, a partnership deal, or some other force of change requires an analytical methods transfer. You should be preparing for that day. Join Bioprocess Online Live on December 3rd for best practices to ensure the methods you're developing today are seamlessly transferrable tomorrow. Registration is free thanks to the support of BD Bioscience.
Inside J&J's Many-Indication mAb

Oct 30, 2024 | bioprocessonline.com | Tyler Menichiello |Matt Pillar

By Tyler Menichiello, contributing editor and Matt Pillar, chief editor Leona Ling, Ph.D.’s relationship with the investigational monoclonal antibody nipocalimab is defined by curiosity, perseverance, and commitment. Dr. Ling, who currently serves in a weighty position with the equally weighty title of Head, Translational Science Autoantibody Pathway Area Stronghold at The Janssen Pharmaceutical Companies of Johnson & Johnson, is humble.
07.23.24 -- Biotech Doesn't Take Vacations

Jul 23, 2024 | bioprocessonline.com | Matt Pillar |Ben Comer |Louis Garguilo |Anna Welch

In the business of WuXi, Lineage Cell Therapeutics, Syncromune, Claris Bio, and more!It's summertime, and the livin' is easy, but the Business of Biotech and Bioprocess Online have been hopping.
The AI Impact with Generate:Biomedicines' Mike Nally on Apple Podcasts

Mar 25, 2024 | podcasts.apple.com | Matt Pillar

Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence.
03.19.24 -- Business of Biotech Newsletter

Mar 19, 2024 | bioprocessonline.com | Matt Pillar |Ben Comer

In the business of Biogen, Eisai, Addimmune, Gates MRI, and more! We Have A PR Problem The Business of Biotech gets quite a bit of fan mail, mostly from listeners in the industry who enjoy the insight gleaned from a couple of humans casually talking shop. Last month, however, we got some angry mail. One guy said I’m on the wrong side of history for discussing the advance of mRNA vaccines with Ethris’ Carsten Rudolph on episode 187.